Stockholm - Free Realtime Quote SEK

CombiGene AB (publ) (COMBI.ST)

Compare
2.5600 -0.0600 (-2.29%)
As of 4:38 PM GMT+1. Market Open.
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
922.1170
5,544.1170
26,699.2820
84,041.5710
--
Operating Expense
40,942.1050
44,144.1050
46,161.3660
63,447.7780
29,360.8800
Operating Income
-40,019.9880
-38,599.9880
-19,462.0840
20,593.7930
-29,360.8800
Net Non Operating Interest Income Expense
2,939.5850
2,934.5850
790.1450
0.0240
-1,392.0770
Pretax Income
-37,080.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,551.4300
Net Income Common Stockholders
-37,080.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
Diluted NI Available to Com Stockholders
-37,080.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
Basic EPS
-1.87
-1.80
-0.31
1.21
-3.31
Diluted EPS
-1.87
-1.80
-0.31
1.21
-3.31
Basic Average Shares
19,801.1970
19,801.1970
19,801.1970
17,311.4140
8,939.0080
Diluted Average Shares
19,801.1970
19,801.1970
19,801.1970
17,311.4140
8,939.0080
Total Operating Income as Reported
--
-38,599.9880
-6,947.0750
20,964.8910
-28,159.3530
Total Expenses
40,942.1050
44,144.1050
46,161.3660
63,447.7780
29,360.8800
Net Income from Continuing & Discontinued Operation
-37,080.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
Normalized Income
-37,080.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
Interest Income
--
2,939.3860
791.8270
0.0240
0.0050
Interest Expense
--
4.8010
1.6820
--
1,392.0820
Net Interest Income
2,939.5850
2,934.5850
790.1450
0.0240
-1,392.0770
EBIT
-37,080.6020
-35,660.6020
-6,155.2490
20,964.9150
-28,159.3480
EBITDA
-34,349.4340
-33,036.4340
-3,560.4210
23,559.7430
-25,664.5200
Reconciled Depreciation
2,731.1680
2,624.1680
2,594.8280
2,594.8280
2,494.8280
Net Income from Continuing Operation Net Minority Interest
-37,080.4030
-35,665.4030
-6,156.9310
20,964.9150
-29,382.7790
Normalized EBITDA
-34,349.4340
-33,036.4340
-3,560.4210
23,559.7430
-25,664.5200
12/31/2020 - 5/25/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ABERA.ST Abera Bioscience AB
3.8600
-0.26%
 
8WK.F Abera Bioscience AB
0.3130
+1.29%
 
LPGO.ST Lipigon Pharmaceuticals AB (publ)
0.1372
+1.03%
 
ELIC.ST Elicera Therapeutics AB (publ)
1.8700
-0.27%
 
IRLAB-A.ST IRLAB Therapeutics AB (publ)
12.85
-1.91%
 
IMMU.ST Mendus AB (publ)
9.24
-0.87%
 
FLUI.ST Fluicell AB (publ)
0.0528
-4.35%
 
SCOL.ST Scandion Oncology A/S
0.0795
-3.64%
 
KAN.ST Kancera AB (publ)
1.0680
-3.61%
 
BINV.ST BioInvent International AB (publ)
46.10
-2.95%